EUCTR2018-003612-45-AT进行中（未招募）1 期
TREATMENT RESISTANCE FOLLOWING ANTI-CANCER THERAPIES (TRANSLATE)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Pfizer Inc.
- 入组人数
- 550
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Histological diagnosis of locally advanced (primary or recurrent) or metastatic solid tumors treated as follows:
- •a. NSCLC monotherapy (Cohort 1):
- •- Disease progression (PD) on 1st-line monotherapy anti-PD-1/-L1.
- •b. NSCLC combination (Cohort 2):
- •- PD on 1st-line anti-PD-1/-L1 plus standard doublet platinum-containing regimen; or
- •- PD on 1st -line anti-PD-1/-L1 plus standard doublet platinumcontaining
- •regimen followed by continuation of single agent anti-PD-1/-
- •c. Renal cell carcinoma (RCC) with clear cell component (Cohort 3):
- •- PD on 2nd-line monotherapy anti-PD-1/-L1; or
- •- PD on 1st-line combination of doublet anti- PD-1/-L1 with anti-CTLA-4; or
- •- PD on 1st-line combination of avelumab with axitinib or pembrolizumab
- •with axitinib.
- •d. HR+ HER2- adenocarcinoma of the breast (Cohort 4):
- •- PD on 1st-line combination of doublet palbociclib with hormonal therapy.
- •e. Castrate-resistant adenocarcinoma of the prostate (Cohort 5):
- •- PD on enzalutamide monotherapy.
- •f. Castrate-resistant adenocarcinoma of the prostate (Cohort 6):
- •- PD on abiraterone in combination with prednisone.
- •g. germline mutated BRCA (gBRCAm), HER2- adenocarcinoma of the breast (Cohort 7):
- •- PD on a PARP inhibitor monotherapy in patients previously treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting.
- •2. Radiographic evidence of PD, including the target lesion being subjected to biopsy for the study, on the most recent regimen that requires a change in anti-cancer treatment.
- •3. Medically stable for a biopsy procedure as defined by the local institutional
- •guidelines.
- •4. A tumor lesion for the de novo biopsy that meets the following criteria:
- •a. Is safely accessible to a biopsy procedure (ie, core needle, excisional) performed in accordance with local institutional practice standards;
- •b. Is anticipated to yield an amount of tumor tissue sufficient to meet the objectives of the study;
- •c. Not previously irradiated;
- •d. Does not require decalcification for subsequent processing.
- •5. Availability and adequacy of an archival, formalin-fixed, paraffin embedded (FFPE) tumor tissue block confirmed during Screening as
- •containing sufficient tumor tissue to allow for sectioning of up to 25 slides each containing tissue sections that are 5 microns thick with a minimum tissue cross-sectional area of approximately 5 mm2 and containing a minimum of approximately 20-40% tumor by ratio of tumor nuclei to benign nuclei. Fewer slides may be required for FFPE tissue blocks containing tissue that is greater than 5 mm2 in cross-sectional area or greater than 40% tumor. Where local or regional regulations prevent submission of the archival tumor tissue block, a designated number of unstained slides each containing the indicated minimum amount of tissue must be submitted (refer to the Laboratory Manual for the required number of slides based on cross sectional area of tissue available in the FFPE tissue block).
- •6. Post-progression biospecimen collection can be performed within 45 days of obtaining informed consent for the study.
- •7. Post-progression biospecimen collection can be performed within 45 days of the last dose of the most recent anti-cancer regimen.
- •8. Age >=18 years at the time of informed consent.
- •9. Patients who are willing and able to comply with scheduled visits and study procedures.
- •10. Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study.
- •Are the trial sub
排除标准
- •1. Discontinuation of current or most recent anti-cancer therapy due to toxicity and not progressive disease.
- •2. Initiation of new anti-cancer therapy after PD prior to planned biopsy.
- •3. Any medical condition that, in the investigator’s judgement, unacceptably increases risk associated with the tumor biopsy or blood sampling procedures (eg, evidence of inadequate wound healing, significant neutropenia or thrombocytopenia, recent history of clinically significant bleeding or tumor hemorrhage).
- •4. Cohorts 1, 2 and 3 (NSCLC monotherapy, NSCLC combination, RCC with clear cell component) only: Treatment with an anti-PD-1/-L1 agent prior to current or most recent anti-PD-1/-L1 therapy.
- •5. Cohort 4 (HR+ HER2- breast cancer) only: Treatment with a CDK 4/6 inhibitor prior to current or most recent CDK 4/6 inhibitor.
- •6. Cohort 5 (castrate-resistant prostate cancer) only: Treatment with an agent that blocks adrenal androgen synthesis (eg, abiraterone acetate) and a second-generation AR antagonist other than enzalutamide (eg,
- •apalutamide).
- •7. Patients who are investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or patients who are Pfizer employees, including their family members, directly involved in the conduct of the study.
- •8. Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study.
- •9. Austria only: Pregnant female patients; breastfeeding female patients.
研究者
相似试验
进行中（未招募）
1 期
TREATMENT RESISTANCE FOLLOWING ANTI-CANCER THERAPIES (TRANSLATE)CancerEUCTR2018-003612-45-ESPfizer Inc.550
招募中
不适用
nraveling tumor response and resistance to combined chemotherapy and PD-L1 inhibition with minimal invasive techniques in patients with advanced NSCLC with targetable disease10027656Lung CancerNon-small cell lung cancerNL-OMON54889niversitair Medisch Centrum Groningen100
终止
不适用
Treatment Resistance Following Anti-cancer TherapiesDisease ProgressionNCT04436120Pfizer38
尚未招募
不适用
Research on the mechanism of resistance to treatment of pituitary adenomaspituitary adenomaJPRN-UMIN000043863agoya university graduate school of medicine100
招募中
不适用
ong-term maintenance of anti-tumor immune responses by vaccination with tri-WT1 peptide cancer vaccine WT1 TrioThymic cancer Thymoma Soft tissue sarcoma Malignant glioma Salivary gland cancer Head and neck mucoepidermoid carcinoma Olfactory neuroblastoma Head and neck mucosal malignant melanoma Ophthalmic malignant melanoma Cancer of the external auditory canal Testicular cancer Cancer of penis Adrenal cancer Malignant mesothelioma Cancer of the small intestine Merkel cell carcinoma Cutaneous lymphoma (Rare cancers listed above)JPRN-UMIN000023578Osaka University Graduate School of Medicine Dept. Cancer Immunotherapy90